Osaka-based Kobayashi Pharmaceutical is currently investigating 76 additional deaths that may be associated with its cholesterol-lowering supplement, \"Benikoji,\" which contains red yeast rice. The company reported receiving 1,656 inquiries from individuals seeking medical attention related to the supplement.
Previously, five deaths had been officially recorded by Japan's health ministry in connection with \"Benikoji.\" The recent surge in cases has intensified scrutiny on the company's handling of the situation.
Kobayashi Pharmaceutical has faced criticism for delaying public disclosure of the internal issues related to the supplement. Problems were reportedly known within the company as early as January, but the first public announcement was only made on March 22. This delayed response has raised concerns among consumers and health advocates about the company's transparency and commitment to consumer safety.
The investigation highlights the growing demand for accountability in the health supplement industry, where safety and efficacy are paramount for consumer trust. As the probe continues, stakeholders are closely watching how Kobayashi Pharmaceutical will address the mounting concerns and ensure the well-being of its customers.
Reference(s):
cgtn.com
